CStone received approval to initiate clinical development in China of CS1001 and BLU-554 (CS3008) in combination therapy for HCC Read more
Reata Receives Orphan Drug Designation for Bardoxolone Methyl for the Treatment of Autosomal Dominant Polycystic Kidney Disease Read more
Cambrex Completes New Process and Analytical Development Facility at its Karlskoga, Sweden Manufacturing Site Read more
FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes Read more